424870 — ImmuneOncia therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩727bn
- KR₩703bn
- KR₩111m
Annual cashflow statement for ImmuneOncia therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | 8,864 | -5,687 | -27,363 |
| Depreciation | |||
| Amortisation | |||
| Non-Cash Items | -19,059 | -5,705 | -106 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 827 | -4,322 | 3,803 |
| Change in Accounts Receivable | |||
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Change in Taxes Payable | |||
| Change in Other Liabilities | |||
| Other Operating Cash Flow | |||
| Cash from Operating Activities | -8,337 | -14,663 | -22,775 |
| Capital Expenditures | -428 | -139 | -468 |
| Purchase of Fixed Assets | |||
| Purchase / Acquisition of Intangibles | |||
| Other Investing Cash Flow Items | -4,903 | 1,867 | -12,646 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Other Investing Cash Flow | |||
| Cash from Investing Activities | -5,332 | 1,728 | -13,114 |
| Financing Cash Flow Items | — | -3.18 | -69.1 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 7,896 | 200 | 35,900 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -5,773 | -12,731 | 11.3 |